Holen Sie sich die Stockscreener-App
1.2158
2.60%
0.0308
Handel nachbörslich:
1.18
-0.0358
-2.94%
Schlusskurs vom Vortag:
$1.185
Offen:
$1.18
24-Stunden-Volumen:
3,180
Relative Volume:
0.06
Marktkapitalisierung:
$3.26M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-4.69M
KGV:
-0.5218
EPS:
-2.33
Netto-Cashflow:
$-3.81M
1W Leistung:
-4.27%
1M Leistung:
+0.48%
6M Leistung:
-34.28%
1J Leistung:
-64.45%
1-Tages-Spanne:
$1.17
$1.2158
1-Wochen-Bereich:
$1.17
$1.29
52-Wochen-Spanne:
$1.02
$3.74
Lixte Biotechnology Holdings Inc Stock (LIXT) Company Profile
Firmenname
Lixte Biotechnology Holdings Inc
Sektor
Branche
Telefon
310 203 2902
Adresse
248 ROUTE 25A, EAST SETAUKET
Vergleichen Sie LIXT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LIXT
Lixte Biotechnology Holdings Inc
|
1.2158 | 3.26M | 0 | -4.69M | -3.81M | -2.33 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Lixte Biotechnology Holdings Inc Aktie (LIXT) Neueste Nachrichten
LIXTE Launches New Study to Determine if Certain - GlobeNewswire
Major Breakthrough? LIXTE's Cancer Prevention Drug Could Eliminate Pre-Cancerous Cells in Aging Adults - Stock Titan
LIXTE Biotechnology Updates Progress On LB-100 In Ovarian And Colorectal Cancer Trials - Nasdaq
LIXTE Biotechnology Provides Update On Progress with - GlobeNewswire
Major Breakthrough: LIXTE's Cancer Drug Shows Promise in New GSK, Roche Clinical Trials - Stock Titan
Lixte Biotechnology Holdings Inc. (LIXT) reports earnings - Quartz
Lixte Biotechnology revises sarcoma study agreement By Investing.com - Investing.com Australia
Lixte Biotechnology revises sarcoma study agreement - Investing.com
Lixte Biotech ends sales agreement, explores funding options By Investing.com - Investing.com South Africa
Lixte Biotechnology terminates sales agreement with Wallachbeth Capital -March 11, 2025 at 10:35 am EDT - Marketscreener.com
Lixte Biotech ends sales agreement, explores funding options - Investing.com
New Findings Show how LIXTE’s Lead Clinical Compound, LB-100, is Metabolized to its Active Form - GlobeNewswire
New Research Reveals Key Mechanism Behind LIXT's Cancer Drug LB-100 - StockTitan
LIXTE Adds Northwestern University’s Lurie Cancer Center as - GlobeNewswire
LIXTE Biotechnology Teams Up with Lurie Cancer Center to Initiate Clinical Trial of LB-100 and GSK’s Dostarlimab for Ovarian Clear Cell Cancer - Nasdaq
Can LIXTE's Cancer Drug Breakthrough Succeed Where Others Failed? Northwestern Joins Trial - StockTitan
Lixte Biotechnology faces Nasdaq delisting over equity shortfall By Investing.com - Investing.com Australia
Lixte Biotechnology faces Nasdaq delisting over equity shortfall - Investing.com India
Lixte Biotechnology Holdings, Inc. Announces Successful Closure of $1.05 Million Offering - Defense World
Lixte Biotechnology announces closing of $1.05M registered direct offering - Yahoo Finance
LIXTE Biotechnology Announces Closing of $1.05 Million - GlobeNewswire
Lixte Biotechnology Closes $1.1 Million Direct Offering -February 13, 2025 at 11:06 am EST - Marketscreener.com
LIXTE Biotechnology Holdings, Inc. Completes Registered Direct Offering and Private Placement Raising Approximately $1.05 Million - Nasdaq
LIXTE Secures Critical $1.05M Funding: Strategic Move Unlocks Next Growth Phase - StockTitan
LIXTE Biotechnology announces $1.05M registered direct offering; shares fall - MSN
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
LIXTE Biotechnology Announces $1.05 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - The Manila Times
LIXTE Biotech (LIXT) Secures Fresh Capital: Strategic $1.05M Direct Offering Includes Warrant Sweetener - StockTitan
Lixte Biotechnology Holdings Inc Inc. (LIXT) Price Performance: A Fundamental Analysis Perspective - The InvestChronicle
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
LIXTE Biotechnology Submits Request for Withdrawal of Form S-1 Registration Statement - GlobeNewswire
Lixte Biotechnology enters agreement for at-the-market stock sale - Investing.com
Lixte Biotechnology Holdings, Inc. Enters into At-the-Market Sales Agreement with WallachBeth Capital, LLC - Defense World
Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) Short Interest Update - Defense World
Lixte Biotechnology Holdings, Inc. Vice President and COO Resigns - Defense World
Lixte Biotechnology announces executive departure By Investing.com - Investing.com Nigeria
Lixte Biotechnology announces executive departure - Investing.com
US Penny Stocks To Watch In December 2024 - Simply Wall St
LIXT (Lixte Biotechnology Holdings) 3-Year Sharpe Ratio : -0.39 (As of Dec. 05, 2024) - GuruFocus.com
LIXTE Biotechnology inks amendment to cancer drug study agreement - Investing.com
LIXTE Biotechnology inks amendment to cancer drug study agreement By Investing.com - Investing.com Nigeria
Lixte Biotechnology Holdings, Inc. Enters into Development Collaboration Agreement with the Netherlands Cancer Institute, Amsterdam - Marketscreener.com
Lixte Biotechnology Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
LIXTW (Lixte Biotechnology Holdings) Accounts Payable & Acc - GuruFocus.com
Pre-market Movers: REVB, CDIO, SMLR, DWTX... - RTTNews
LIXT stock touches 52-week low at $1.53 amid market challenges - Investing.com Australia
Why VF Corp Shares Are Trading Higher By Around 21%; Here Are 20 Stocks Moving Premarket - Benzinga
LIXT stock touches 52-week low at $1.53 amid market challenges By Investing.com - Investing.com South Africa
Finanzdaten der Lixte Biotechnology Holdings Inc-Aktie (LIXT)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.01%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):